AbolerIS Pharma

Today, we mark a significant milestone – 5 incredible years of dedication, and innovation in life science. AbolerIS Pharma is developing novel and unique therapeutic approaches to finely regulate the immune system by inducing immune tolerance and preserving useful immune responses in inflammatory, autoimmune, and degenerative diseases. Our innovative therapy restores immune balance, offering hope for long-lasting remission in autoimmune diseases like rheumatoid arthritis. This approach addresses unmet needs, transforming care for patients worldwide. As we celebrate this milestone, a heartfelt thank you to everyone who believed in us and supported us throughout this incredible journey. We look forward to the future with renewed energy and commitment. Together, we build something truly impactful. ❤

👋 𝐄𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐧𝐞𝐰𝐬 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐀𝐛𝐨𝐥𝐞𝐫𝐈𝐒 𝐭𝐞𝐚𝐦! On behalf of our team, Ronald Van Brempt and Carole Guillonneau will attend the 𝐀𝐦𝐞𝐫𝐢𝐜𝐚𝐧 𝐂𝐨𝐥𝐥𝐞𝐠𝐞 𝐨𝐟 𝐑𝐡𝐞𝐮𝐦𝐚𝐭𝐨𝐥𝐨𝐠𝐲 (𝐀𝐂𝐑) 𝐀𝐧𝐧𝐮𝐚𝐥 𝐌𝐞𝐞𝐭𝐢𝐧𝐠 in Washington, D.C, one of the leading global conferences for advancements in rheumatology. We’re especially proud to share that Carole Guillonneau will be presenting a poster titled, "𝑬𝒍𝒊𝒎𝒊𝒏𝒂𝒕𝒊𝒐𝒏 𝒐𝒇 𝑪𝑫45𝑹𝑪𝒉𝒊𝒈𝒉 𝑻 𝒂𝒏𝒅 𝑩 𝒄𝒆𝒍𝒍𝒔 𝒃𝒚 𝒂𝒏 𝒂𝒏𝒕𝒊-𝑪𝑫45𝑹𝑪 𝒂𝒏𝒕𝒊𝒃𝒐𝒅𝒚 𝒍𝒆𝒂𝒅𝒔 𝒕𝒐 𝒆𝒇𝒇𝒊𝒄𝒊𝒆𝒏𝒕 𝒄𝒐𝒏𝒕𝒓𝒐𝒍 𝒐𝒇 𝒆𝒙𝒑𝒆𝒓𝒊𝒎𝒆𝒏𝒕𝒂𝒍 𝒓𝒉𝒆𝒖𝒎𝒂𝒕𝒐𝒊𝒅 𝒂𝒓𝒕𝒉𝒓𝒊𝒕𝒊𝒔." Our research dives into a promising approach to controlling rheumatoid arthritis by targeting specific immune cells—a step towards better treatments for those affected by chronic conditions. If you're attending the ACR meeting, we’d love to connect and discuss innovations in rheumatology. Stayed tuned for more exciting updates! #ACR24 #Rheumatology #Research

🌟 Exciting news – we are not just attending the 𝐄𝐔𝐋𝐀𝐑 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬 2024 𝐢𝐧 𝐕𝐢𝐞𝐧𝐧𝐚 but also presenting there! We're proud to share that Ronald Van Brempt from AbolerIS Pharma will be presenting our team’s innovative research titled: 𝐄𝐥𝐢𝐦𝐢𝐧𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐂𝐃45𝐑𝐂𝐡𝐢𝐠𝐡 𝐓 𝐚𝐧𝐝 𝐁 𝐜𝐞𝐥𝐥𝐬 𝐛𝐲 𝐚𝐧𝐭𝐢-𝐂𝐃45𝐑𝐂 𝐦𝐀𝐛 𝐥𝐞𝐚𝐝𝐬 𝐭𝐨 𝐞𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐭 𝐜𝐨𝐧𝐭𝐫𝐨𝐥 𝐨𝐟 𝐞𝐱𝐩𝐞𝐫𝐢𝐦𝐞𝐧𝐭𝐚𝐥 𝐫𝐡𝐞𝐮𝐦𝐚𝐭𝐨𝐢𝐝 𝐚𝐫𝐭𝐡𝐫𝐢𝐭𝐢𝐬 on Wednesday in the oral abstract presentations: 𝐑𝐀 𝐩𝐚𝐭𝐡𝐨𝐠𝐞𝐧𝐞𝐬𝐢𝐬 𝐚𝐧𝐝 𝐧𝐨𝐯𝐞𝐥 𝐭𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐭𝐚𝐫𝐠𝐞𝐭𝐬! The groundbreaking discoveries of our team could substantially improve the management of patients across a wide range of autoimmune disorders! Stay tuned for more updates! #EULAR2024 #Rheumatology #autoimmune #HealthcareInnovation #AbolerISPharma

🎉 Congress News – The AbolerIS Pharma team is gearing up to Vienna for the 𝐄𝐔𝐋𝐀𝐑 𝐂𝐨𝐧𝐠𝐫𝐞𝐬𝐬 2024 organized by EULAR - European Alliance of Associations for Rheumatology! 🎉 Ann Meulemans, Jannie Ausma, Ronald Van Brempt, and Katleen Swinnen, PhD are super excited to dive into the world of rheumatology with the best and brightest in the field. We are eager to 🤝 Connect with experts in the field 🔍 Get the latest insights into rheumatology 🌐 Explore groundbreaking research and advancements If you're going to be there, let’s connect, we are ready to chat, connect, and learn. Let’s make this congress unforgettable! See you in Vienna! #EULAR2024 #RheumatologyRocks #AbolerISPharma #HealthcareInnovation #Networking

🚀 Les startups à impact trouvent un terrain fertile à #Nantes et #SaintNazaire pour se développer ! En 2023, malgré un climat économique incertain, les startups à impact sur notre territoire ont brillé en levant 177 millions d'euros. 👏 Bravo à ces initiatives portant un impact social et environnemental : AbolerIS Pharma ➡️ 27,3 M€ pour un traitement innovant contre la polyarthrite rhumatoïde, illustrant le potentiel de la recherche issue de Nantes Université. Beem Energy ➡️ 20 M€ pour accélérer la transition énergétique en France et en Europe, confirmant son rôle de pionnier dans la maîtrise de l'#énergie. FAGUO ➡️ 15 M€ pour étendre son engagement en faveur d'une mode plus responsable, en intégrant plus de matières recyclées dans ses collections. Ecov ➡️ 11,75 M€ pour développer son modèle de mobilité durable et répondre aux défis de la transition écologique dans les zones périurbaines et rurales. Sunology ➡️ 10 M€ pour soutenir sa croissance et son expansion en Europe, mettant en lumière son innovation dans le domaine de l'énergie solaire. Bout' à Bout' ➡️ 7,3 M€ pour lancer la plus grande usine de lavage de bouteilles en France à Carquefou, près de Nantes, révolutionnant le #réemploi des contenants en verre. Retrouvez notre article complet 👉 https://lnkd.in/eW9Ktdke Source : La Cantine Numérique #DevEco #Impact #financement #entrepreneuriat 👋 Nantes Métropole, Nantes Métropole Entreprises, CCI Nantes St-Nazaire, Saint-Nazaire et agglomération